The therapy is meant to combat as much cancer as possible before a patient undergoes surgery to remove any remaining tumor in the pancreasand indeed, the phase II clinical trial demonstrated that it's effective in doing so. In this latest work, which is published in Clinical Cancer Research, investigators analyzed ...
"This triple combination therapy led to an unprecedented curative response in our models," said corresponding author Ronald DePinho, M.D., professor of Cancer Biology. "The prevailing view has been that pancreatic cancer is impervious to immunotherapy, but this preclinical study shows that it can be vulnerable to the right combination therapy. ...
"Stress granule research is exploding right now, but there's still a lot we don't know regarding what they're made of and how they work," says Dr. Grabocka, who is a researcher with the Sidney Kimmel Cancer Center - Jefferson Health and an assistant professor at Thomas Jefferson University. "This work ...
